CTIS | Posters & Presentations Genentech, South San Francisco, CA, USA | 15th October 08:30am – 5:30pm PST We’re excited to announce that our team will be attending the 2nd Annual Clinical Trial Innovation Summit 2025 This years Clinical Trial Innovation Summit brings together global leaders driving the future of clinical research and we’re proud […]
CTIS | Posters & Presentations Read More »
ISCTM and ECNP | Posters & Presentations Amsterdam, Netherlands | ISCTM: 9-11th October | ECNP: 11-14th October We’re excited to announce that our team will be attending the ISCTM 2025 Autumn Conference and ECNP 38th Congress 2025 This year’s program features world-class discussions on precision psychiatry, psychedelic therapies, and lessons from global clinical trials—and we’re proud to be
ISCTM and ECNP | Posters & Presentations Read More »
How Picture Description Tasks Can Help Track Cognitive Health Remotely Speech as a digital biomarker in clinical research Changes in how we speak—how quickly we talk, how often we pause, and the words we choose—can be early signs of cognitive decline. People with mild cognitive impairment (MCI) or dementia due to Alzheimer’s disease (AD) often
How Picture Description Tasks Can Help Track Cognitive Health Remotely Read More »
Cambridge Cognition Investment, Monument Therapeutics, Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for Schizophrenia 19 August 2025 Cambridge UK, August 19, 2025Â – Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is
Cognition in The Blood (Biomarker) How do digital cognitive assessments relate to the Blood Plasma p-Tau217 in patients with Mild Cognitive Impairment (MCI)? Our latest research explores an exciting dataset with the AI–Mind Project, who have given us the opportunity to test the associations of our cognitive assessments alongside classic paper-and-pencil tests to levels of
Cognition in The Blood (Biomarker) Read More »
Cambridge Cognition launches Speaker Identification Solution to Safeguard Clinical Trial Integrity 12 August 2025 Cambridge Cognition Holdings plc (AIM:COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to announce the commercial launch of a proprietary speaker identification solution developed to tackle duplicate participant enrolment
Trading update for period ended 30 June 2025 31st July 2025 Cambridge Cognition Holdings plc (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, announces a trading update for the six months ended 30 June 2025. Highlights ·    New Sales Orders of £6.9m (H1 2024: £3.3m) ·    Order Book of £16.4m (30
Trading update for period ended 30 June 2025 Read More »
AAIC25 | Posters & Presentations Toronto, Canada | 27th – 31st July | Booth 1531 Unveiling Cutting-Edge Alzheimer’s & Dementia Research at AAIC 2025: A Sneak Peek at Our Latest Posters The Alzheimer’s Association International Conference (AAIC) is just around the corner, and we’re incredibly excited to share some of the latest research our team
AAIC25 | Posters & Presentations Read More »
Cambridge Cognition Investment, Monument Therapeutics, Achieves Positive Phase I Results for Novel Schizophrenia Treatment 23rd June 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to report that Monument Therapeutics, in which the Group has a 20% holding, has achieved
SIRS 2025: Insights on Schizophrenia Research, From Rights Based Care to Digital Biomarkers Michael Spilka, Sr. Clinical Scientist This year’s Schizophrenia International Research Society (SIRS) 2025 Congress in Chicago brought together leading scientists and researchers, exploring the latest advancements and ongoing challenges in understanding and addressing schizophrenia. Michael Spilka, PhD. shares his key insights from
